Controversies in Upfront Consolidations with High Dose Therapy and Stem Cell Transplant: Poor Risk DLBCL and MCL

This information was originally presented on September 14, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the current approaches to treatment of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), including post-remission consolidation or maintenance strategies
  • Identify patients with DLBCL or MCL who are suitable candidates for post-remission treatment approaches
Additional information
Supporters: 

Supported by educational grants from Genentech; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; and sanofi-aventis U.S.

Course summary
Available credit: 
  • 0.50 Participation
  • 0.62 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician
Course opens: 
11/09/2012
Course expires: 
11/09/2013
Cost:
$0.00

Jeremy S. Abramson, MD
Massachusetts General Hospital Cancer Center

Available Credit

  • 0.50 Participation
  • 0.62 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician

Accreditation Period

Course opens: 
11/09/2012
Course expires: 
11/09/2013

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing